SYNACT PHARMA ApS: Financial statements 2022
CVR: 34459975
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
SYNACT PHARMA ApS (CVR 34459975) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -46,951,479 and a net result of DKK -49,780,297 compared with DKK -41,156,629 the year before. Equity in the 2022 report amounted to DKK 33,994,887. The solvency ratio was 89.6%. The company had 3 employees in the financial year.
- Gross Profit
- DKK -46,951,479
- Profit/Loss
- DKK -49,780,297
- Equity
- DKK 33,994,887
- Total Assets
- DKK 37,947,151
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -47 mio. | -49.8 mio. | 34 mio. | 3 |
| 2021 | - | -43.4 mio. | -41.2 mio. | 6.6 mio. | 2 |
| 2020 | - | -16.7 mio. | -14 mio. | 11.4 mio. | - |
| 2019 | - | -11.5 mio. | -9.8 mio. | -21.8 mio. | - |
| 2018 | - | -16.8 mio. | -13.6 mio. | -12 mio. | - |
Keep an eye on SYNACT PHARMA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of August 15, 2022, KPMG P/S has been appointed auditor of SYNACT PHARMA ApS.
As of August 15, 2022, Forvis Mazars Statsautoriseret Revisionspartnerselskab has stepped down as auditor of SYNACT PHARMA ApS.
SYNACT PHARMA ApS has published its annual report for 2021. Gross profit came to DKK -43,429,977, and the net result was DKK -41,156,629.
As of January 18, 2022, Patrik Renblad is registered as director of SYNACT PHARMA ApS.
As of January 18, 2022, Henrik Stage has stepped down as director of SYNACT PHARMA ApS.
About SYNACT PHARMA ApS
SYNACT PHARMA ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named SYNACTION PHARMA ApS. The management consists of Jeppe Øvli Øvlesen, Thomas Boesen and Ann Kristin Brøgger Led. The company is owned by SynAct Pharma AB. In 2025, the company reported a gross profit of DKK -53,194,923 and a net result of DKK -59,812,937 compared with DKK -30,477,376 the year before. Equity in the 2025 report amounted to DKK 20,295,649.